USD
+$0.00
(+0.00%
)At Close (As of Oct 17, 2025)
$22.43B
Market Cap
97.13
P/E Ratio
3.28
EPS
$353.50
52 Week High
$226.50
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $1.4B |
Total Revenue | $2.1B |
Cost Of Revenue | $626M |
Costof Goods And Services Sold | $626M |
Operating Income | $309M |
Selling General And Administrative | $833M |
Research And Development | $220M |
Operating Expenses | $1.1B |
Investment Income Net | - |
Net Interest Income | -$3.2M |
Interest Income | $40M |
Interest Expense | $43M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $81M |
Income Before Tax | $300M |
Income Tax Expense | -$118M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $418M |
Comprehensive Income Net Of Tax | - |
Ebit | $343M |
Ebitda | $424M |
Net Income | $418M |
Field | Value (USD) |
---|---|
Total Assets | $3.1B |
Total Current Assets | $1.9B |
Cash And Cash Equivalents At Carrying Value | $953M |
Cash And Short Term Investments | $953M |
Inventory | $430M |
Current Net Receivables | $366M |
Total Non Current Assets | $1.2B |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $99M |
Intangible Assets Excluding Goodwill | $99M |
Goodwill | $52M |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $122M |
Other Non Current Assets | - |
Total Liabilities | $1.9B |
Total Current Liabilities | $528M |
Current Accounts Payable | $20M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $86M |
Total Non Current Liabilities | $1.3B |
Capital Lease Obligations | - |
Long Term Debt | $1.3B |
Current Long Term Debt | $96M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $1.4B |
Other Current Liabilities | $411M |
Other Non Current Liabilities | $52M |
Total Shareholder Equity | $1.2B |
Treasury Stock | - |
Retained Earnings | $40M |
Common Stock | $100K |
Common Stock Shares Outstanding | $74M |
Field | Value (USD) |
---|---|
Operating Cashflow | $430M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $81M |
Capital Expenditures | $125M |
Change In Receivables | - |
Change In Inventory | -$32M |
Profit Loss | - |
Cashflow From Investment | -$146M |
Cashflow From Financing | -$28M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | $12M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $418M |
Field | Value (USD) |
---|---|
Gross Profit | $1.4B |
Total Revenue | $2.1B |
Cost Of Revenue | $626M |
Costof Goods And Services Sold | $626M |
Operating Income | $309M |
Selling General And Administrative | $833M |
Research And Development | $220M |
Operating Expenses | $1.1B |
Investment Income Net | - |
Net Interest Income | -$3.2M |
Interest Income | $40M |
Interest Expense | $43M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $81M |
Income Before Tax | $300M |
Income Tax Expense | -$118M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $418M |
Comprehensive Income Net Of Tax | - |
Ebit | $343M |
Ebitda | $424M |
Net Income | $418M |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
Insulet Corporation (PODD) is a pioneering company in the field of insulin delivery systems, dedicated to enhancing the quality of life for individuals with insulin-dependent diabetes through innovative technology. Based in Acton, Massachusetts, Insulet is renowned for its Omnipod® Insulin Management System, a revolutionary tubeless, wearable pump that provides patients with unprecedented flexibility and ease of use. With a robust commitment to advancing diabetes care, Insulet is actively expanding its technological offerings and global footprint, solidifying its position as a leader in the diabetes management market.